RYR2 and catecholaminergic polymorphic ventricular tachycardia: Genetic testing primarily includes panel testing for genes with definitive and strong evidence for CPVT (see Table 8) as well as genes with moderate evidence, such as CALM 1–3 (locus 14q32.11, 2p21, and 19q13.32), which affect RyR2 binding affinity and lead to inappropriate Ca2+ release from the sarcoplasmic reticulum (SR).